Drug intelligence / Profile preview

[18F]AlF-NOTA-PEG2-ECL1i

Development stage: Unknown
Lead developer: Chinese Academy of Medical Sciences and Peking Union Medical College
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals

Overview

[18F]AlF-NOTA-PEG2-ECL1i: sourced facts only. name: "In this study, we developed an 18F-labeled CCR2-targeted positron emission tomography (PET) radiotracer, [18F]AlF-NOTA-PEG2-ECL1i, for the noninvasive imaging of cardiac inflammation." [PMID:42150152]; target: "In this study, we developed an 18F-labeled CCR2-targeted positron emission tomography (PET) radiotracer, [18F]AlF-NOTA-PEG2-ECL1i, for the noninvasive imaging of cardiac inflammation." [PMID:42150152]; developer: "Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China." [PMID:42150152]; modality: "In this study, we developed an 18F-labeled CCR2-targeted positron emission tomography (PET) radiotracer, [18F]AlF-NOTA-PEG2-ECL1i, for the noninvasive imaging of cardiac inflammation." [PMID:42150152]

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)

Beyond the preview

Go deeper on [18F]AlF-NOTA-PEG2-ECL1i.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]AlF-NOTA-PEG2-ECL1i.